Measures of lung epithelial injury might be particularly useful in selecting patients likely to benefit from lung-epithelial targeted therapies such as keratinocyte growth factor [28-30] in future clinical trials in ARDS. This evidence concerns the gene FGF7 and acute respiratory distress syndrome.